Skip to main content
SpringerLink
Log in

Indirect comparisons of treatment effects in multiple sclerosis

  • Letter to the Editors
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Del Santo F, Maratea D, Fadda V, Trippoli S, Messori A (2011) Treatments for relapsing-remitting multiple sclerosis: summarising current information by network meta-analysis. Eur J Clin Pharmacol. doi:10.1007/s00228-011-1141-1

  2. Inusah S, Sormani MP, Cofield SS, Aban IB, Musani SK, Srinivasasainagendra V, Cutter GR (2010) Assessing changes in relapse rates in multiple sclerosis. Mult Scler 16(12):1414–1421

    Article  PubMed  Google Scholar 

  3. The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43(4):655–661

    Article  Google Scholar 

  4. PRISMS Study Group (1998) Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 352(9139):1498–1504

    Article  Google Scholar 

  5. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW, AFFIRM Investigators (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354(9):899–910

    Article  PubMed  CAS  Google Scholar 

  6. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362(5):387–401

    Article  PubMed  CAS  Google Scholar 

  7. Klawiter E, Cross AH, Naismith RT (2009) The present efficacy of multiple sclerosis therapeutics. Is the new 66% just the old 33%? Neurology 73(12):984–990

    Article  PubMed  CAS  Google Scholar 

  8. Sheps M (1958) Shall we count the living of the dead? N Engl J Med 259(25):1210–1214

    Article  PubMed  CAS  Google Scholar 

  9. Walter S (2000) Choice of effect measure for epidemiological data. J Clin Epidemiol 53(9):931–939

    Article  PubMed  CAS  Google Scholar 

  10. Schechtman E (2002) Odds ratio, relative risk, absolute risk reduction, and the number needed to treat—which of these should we use? Value Health 5(5):431–436

    Article  PubMed  Google Scholar 

  11. Panitch H, Goodin DS, Francis G et al (2002) Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE Trial. Neurology 59(10):1496–1506

    Article  PubMed  CAS  Google Scholar 

  12. Comi G, Filippi M, Wolinsky JS, the European/Canadian Glatiramer Acetate Study Group (2001) European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of Glatiramer acetate on magnetic resonance imaging measured disease activity and burden in patients with relapsing-remitting multiple sclerosis. Ann Neurol 49(3):290–297

    Article  PubMed  CAS  Google Scholar 

  13. O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung HP, Jeffery D, Kappos L, Boateng F, Filippov V, Groth M, Knappertz V, Kraus C, Sandbrink R, Pohl C, Bogumil T, BEYOND Study Group, O'Connor P, Filippi M, Arnason B, Cook S, Goodin D, Harung HP, Kappos L, Jeffery D, Comi G (2009) 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 8(10):889–897

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Biostatistics Unit, Department of Health Sciences (DISSAL), University of Genoa, Via Pastore 1, Genoa, 16132, Italy

    Maria Pia Sormani & Alessio Signori

Authors
  1. Maria Pia Sormani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alessio Signori
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maria Pia Sormani.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sormani, M.P., Signori, A. Indirect comparisons of treatment effects in multiple sclerosis. Eur J Clin Pharmacol 68, 1227–1228 (2012). https://doi.org/10.1007/s00228-012-1246-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-012-1246-1

Keywords

Search

Navigation